Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GNCA vs. SMFL, SCPS, VAXX, TRVN, ARDS, NAVB, GNCAQ, STAB, EVLO, and AMPEShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCAQ), Statera Biopharma (STAB), Evelo Biosciences (EVLO), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Smart for Life Scopus BioPharma Vaxxinity Trevena Aridis Pharmaceuticals Navidea Biopharmaceuticals Genocea Biosciences Statera Biopharma Evelo Biosciences Ampio Pharmaceuticals Genocea Biosciences (NASDAQ:GNCA) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment. Which has preferable valuation & earnings, GNCA or SMFL? Smart for Life has higher revenue and earnings than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/ASmart for Life$11.11M0.00-$22.68MN/AN/A Do insiders and institutionals have more ownership in GNCA or SMFL? 0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is GNCA or SMFL more profitable? Smart for Life's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Genocea BiosciencesN/A -182.88% -62.76% Smart for Life N/A N/A N/A Does the media favor GNCA or SMFL? In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score. Company Overall Sentiment Genocea Biosciences Neutral Smart for Life Neutral Which has more volatility and risk, GNCA or SMFL? Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Smart for Life has a beta of 16.69, indicating that its stock price is 1,569% more volatile than the S&P 500. SummarySmart for Life beats Genocea Biosciences on 7 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$346.10M$6.13B$10.55BDividend YieldN/AN/A5.72%4.83%P/E Ratio0.00N/A85.7827.06Price / SalesN/A464.94612.92132.30Price / CashN/A22.4425.8230.35Price / BookN/A3.6212.226.58Net Income-$33.20M-$133.30M$3.33B$276.84M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070SMFLSmart for LifeN/A$0.00flatN/A-87.7%$19K$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00-70.0%N/AN/A$13KN/A0.009Gap DownVAXXVaxxinityN/A$0.00flatN/A-50.0%$13KN/A0.0090Gap DownHigh Trading VolumeTRVNTrevena1.4481 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00-91.3%N/AN/A$11KN/A0.0030Gap DownNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070STABStatera BiopharmaN/A$0.00-50.0%N/AN/A$5KN/A0.0020Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$4KN/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020 Related Companies and Tools Related Companies SMFL Competitors SCPS Competitors VAXX Competitors TRVN Competitors ARDS Competitors NAVB Competitors GNCAQ Competitors STAB Competitors EVLO Competitors AMPE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCA) was last updated on 10/20/2025 by MarketBeat.com Staff From Our Partners$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBankrupt to billionaire after retirement?Expert Reveals: The #1 Retirement Play for 2025 "We're Entering the Greatest Energy Bull Market Since the I...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
